ZilvER ptx with cilOstazol in Superficial femoral artery

UMIN ID: UMIN000032473

Registered date:01/06/2018

Basic Information

• Recruitment status: Complete: follow-up continuing
• Health condition(s) or Problem(s) studied: PAD
• Date of first enrollment: 2018/04/01
• Target sample size: 90
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): For SFA lesions Stenting DES(Zilver PTX) 1 year oral administration of Cilostazol

Outcome(s)

• Primary Outcome: TBA

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 100years-old
• Gender: Male and Female
• Exclude criteria: TBA

Related Information

• Primary Sponsor: Department of Cardiovascular Medicine, Shinshu university Hospital
• Source(s) of Monetary Support: Department of Cardiovascular Medicine, Shinshu university Hospital